Effect of prazosin on blood pressure and plasma lipids in patients receiving a beta-blocker and diuretic regimen

Mauersberger, H

doi:10.1016/0002-9343(84)90965-3

Cited by 8 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Evidence is accumulating to suggest that add‐on therapy with an alpha 1 ‐blocker may have a positive effect on the serum lipid profile of hypertensive patients previously treated with a diuretic, beta‐blocker, or other antihypertensive drug 17,24,28,30,31,33 . For example, in the recent placebo controlled study by Black et al 33 of doxazosin add‐on therapy in patients inadequately controlled by one or two antihypertensive drugs, doxazosin led to significant improvements in the levels of total cholesterol (mean ‐18.0 mg/dl, p=0.013) and low‐density lipoprotein cholesterol (mean ‐12.8 mg/dl, p=0.003) 33 …”

Section: Prevention and Treatment Of Concomitant Diseasementioning

confidence: 99%

“…Prazosin was the first alpha 1 ‐blocker available for clinical use. Promising improvements in sitting blood pressure were first observed in small, open label studies examining the addition of prazosin to the regimen of patients with hypertension inadequately controlled with a beta‐blocker plus a diuretic 17,18 …”

Section: Improvements In Blood Pressure Control With Add‐on Therapymentioning

confidence: 99%

See 1 more Smart Citation

The Role of Alpha1‐blockers in Combination Therapy for Hypertension

2000

Int J Clinical Practice

View full text Add to dashboard Cite

SUMMARYAntihypertensive monotherapy provides adequate blood pressure control in less than 50% of patients with hypertension (BP>140/90 mmHg), especially those with stage 2‐3 disease. This article reviews clinical studies that demonstrate that add‐on therapy with an alpha1‐blocker (doxazosin, terazosin or prazosin) is an effective and well‐tolerated regimen for improving blood pressure control in patients with inadequately controlled hypertension. Furthermore, alpha1‐blockers have therapeutic benefits that go beyond blood pressure management. They have a small but positive effect on the serum lipid profile and they have favourable or benign effects on conditions that frequently coexist with hypertension, such as type 2 diabetes mellitus and benign prostatic hyperplasia. (Int J Clin Pract 2000; 54(1): 36‐41)

show abstract

Section: Prevention and Treatment Of Concomitant Diseasementioning

confidence: 99%

Section: Improvements In Blood Pressure Control With Add‐on Therapymentioning

confidence: 99%